Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KYNTRA BIO, INC.FGEN · Entity 7431 | Director · Chief Executive Officer | August 21, 2019 | August 23, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KYNTRA BIO, INC.
Report date August 21, 2019 · Filed August 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,326,612 |
Ending reported balance
After 2019-08-22 transaction · row 6
5 source rows · reconciled sequenceRow 1 · 2019-08-21 · Exercise / conversion · Acquired 6,834 · Balance 2,356,578 Row 2 · 2019-08-21 · Sale · Disposed 18,400 · Balance 2,338,178 F1: Shares sold pursuant to a 10b5-1 plan. F2: The shares were sold at prices ranging from $44.54 to $45.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 4 · 2019-08-22 · Exercise / conversion · Acquired 6,834 · Balance 2,345,012 Row 5 · 2019-08-22 · Sale · Disposed 17,100 · Balance 2,327,912 F1: Shares sold pursuant to a 10b5-1 plan. F4: The shares were sold at prices ranging from $43.46 to $44.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 6 · 2019-08-22 · Sale · Disposed 1,300 · Balance 2,326,612 F1: Shares sold pursuant to a 10b5-1 plan. F5: The shares were sold at prices ranging from $44.61 to $44.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Partnership | 45,656 |
Reported balance
After 2019-08-21 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2019-08-21 · Sale · Disposed 1,418 · Balance 45,656 F1: Shares sold pursuant to a 10b5-1 plan. F3: The shares were sold at prices ranging from $44.51 to $45.115. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Partnership | 44,238 |
Reported balance
After 2019-08-22 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2019-08-22 · Sale · Disposed 1,418 · Balance 44,238 F1: Shares sold pursuant to a 10b5-1 plan. F6: The shares were sold at prices ranging from $43.47 to $43.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2020-06-09 | Direct | 184,536 |
Reported balance
After 2019-08-21 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-08-21 · Exercise / conversion · Disposed 6,834 · Balance 184,536 F8: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2020-06-09 | Direct | 177,702 |
Reported balance
After 2019-08-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-08-22 · Exercise / conversion · Disposed 6,834 · Balance 177,702 F8: Fully vested. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 20,000 |
Reported balance
Holding disclosure · report date 2019-08-21 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 20,000 |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 60,946 |
Reported balance
Holding disclosure · report date 2019-08-21 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 60,946 F7: The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a 10b5-1 plan.
F2: The shares were sold at prices ranging from $44.54 to $45.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: The shares were sold at prices ranging from $44.51 to $45.115. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: The shares were sold at prices ranging from $43.46 to $44.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5: The shares were sold at prices ranging from $44.61 to $44.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6: The shares were sold at prices ranging from $43.47 to $43.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F7: The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.
F8: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2018 Filed Jul 7, 2018 00:02 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,637 | $66.96 | $176,573.52 |
DisclosureSEC source: 0001209191-18-041915 · doc4.xml · nonDerivative · entry 10 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,811,713 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F8 · price: The shares were sold at prices ranging from $66.80 to $67.275. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 06, 2018 Filed Jul 7, 2018 00:02 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 8,723 | $66.16 | $577,113.68 |
DisclosureSEC source: 0001209191-18-041915 · doc4.xml · nonDerivative · entry 9 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,814,350 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F7 · price: The shares were sold at prices ranging from $65.75 to $66.725. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 06, 2018 Filed Jul 7, 2018 00:02 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 5,940 | $65.24 | $387,525.60 |
DisclosureSEC source: 0001209191-18-041915 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,823,073 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $64.75 to $65.70. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 06, 2018 Filed Jul 7, 2018 00:02 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,600 | $64.15 | $102,640.00 |
DisclosureSEC source: 0001209191-18-041915 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,829,013 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $63.75 to $64.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 06, 2018 Filed Jul 7, 2018 00:02 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,320 | $3.60 | $37,152.00 |
DisclosureSEC source: 0001209191-18-041915 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,830,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 05, 2018 Filed Jul 7, 2018 00:02 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,320 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-041915 · doc4.xml · derivative · entry 15 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,901 Underlying: Common Stock · 10,320 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Fully vested. Read SEC document |
| July 05, 2018 Filed Jul 7, 2018 00:02 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 100 | $64.75 | $6,475.00 |
DisclosureSEC source: 0001209191-18-041915 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 106,728 F1 · shares: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
| July 05, 2018 Filed Jul 7, 2018 00:02 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 818 | $63.92 | $52,286.56 |
DisclosureSEC source: 0001209191-18-041915 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 106,828 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $63.50 to $64.25. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 05, 2018 Filed Jul 7, 2018 00:02 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 5,400 | $64.62 | $348,948.00 |
DisclosureSEC source: 0001209191-18-041915 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,820,293 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $64.35 to $65.25. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 05, 2018 Filed Jul 7, 2018 00:02 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 13,500 | $63.97 | $863,595.00 |
DisclosureSEC source: 0001209191-18-041915 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,825,693 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $63.35 to $64.30. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 05, 2018 Filed Jul 7, 2018 00:02 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,320 | $3.60 | $37,152.00 |
DisclosureSEC source: 0001209191-18-041915 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,839,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 21:46 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,320 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-039293 · doc4.xml · derivative · entry 13 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,221 Underlying: Common Stock · 10,320 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Fully vested. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 21:46 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 918 | $63.60 | $58,384.80 |
DisclosureSEC source: 0001209191-18-039293 · doc4.xml · nonDerivative · entry 9 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 107,646 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F8 · price: The shares were sold at prices ranging from $63.20 to $63.975. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 21:46 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 3,728 | $64.08 | $238,890.24 |
DisclosureSEC source: 0001209191-18-039293 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,828,873 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F7 · price: The shares were sold at prices ranging from $64.00 to $64.225. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 21:46 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 15,172 | $63.54 | $964,028.88 |
DisclosureSEC source: 0001209191-18-039293 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,832,601 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $63.10 to $63.975. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 21:46 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,320 | $3.60 | $37,152.00 |
DisclosureSEC source: 0001209191-18-039293 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,847,773 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 21:46 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,320 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-039293 · doc4.xml · derivative · entry 12 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,541 Underlying: Common Stock · 10,320 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Fully vested. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 21:46 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 120 | $63.97 | $7,676.40 |
DisclosureSEC source: 0001209191-18-039293 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 108,564 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $63.95 to $63.975. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 21:46 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 798 | $63.55 | $50,712.90 |
DisclosureSEC source: 0001209191-18-039293 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 108,684 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $62.90 to $63.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 21:46 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 11,199 | $63.79 | $714,384.21 |
DisclosureSEC source: 0001209191-18-039293 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,837,453 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $63.55 to $64.25. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 21:46 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 7,701 | $63.31 | $487,550.31 |
DisclosureSEC source: 0001209191-18-039293 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,848,652 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $62.55 to $63.525. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 21:46 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,320 | $3.60 | $37,152.00 |
DisclosureSEC source: 0001209191-18-039293 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,856,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 23:20 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 6,373 | $56.60 | $360,711.80 |
DisclosureSEC source: 0001209191-18-036789 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,846,033 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| June 05, 2018 Filed Jun 5, 2018 23:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,320 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-035944 · doc4.xml · derivative · entry 14 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,861 Underlying: Common Stock · 10,320 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully vested. Read SEC document |
| June 05, 2018 Filed Jun 5, 2018 23:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 918 | $54.94 | $50,434.92 |
DisclosureSEC source: 0001209191-18-035944 · doc4.xml · nonDerivative · entry 10 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 109,482 F2 · shares: Shares sold pursuant to a 10b5-1 plan. F9 · price: The shares were sold at prices ranging from $54.60 to $55.575. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 05, 2018 Filed Jun 5, 2018 23:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,700 | $55.59 | $150,093.00 |
DisclosureSEC source: 0001209191-18-035944 · doc4.xml · nonDerivative · entry 9 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,852,406 F2 · shares: Shares sold pursuant to a 10b5-1 plan. F8 · price: The shares were sold at prices ranging from $55.45 to $55.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 05, 2018 Filed Jun 5, 2018 23:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 16,200 | $54.93 | $889,866.00 |
DisclosureSEC source: 0001209191-18-035944 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,855,106 F2 · shares: Shares sold pursuant to a 10b5-1 plan. F7 · price: The shares were sold at prices ranging from $54.45 to $55.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 05, 2018 Filed Jun 5, 2018 23:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,320 | $3.60 | $37,152.00 |
DisclosureSEC source: 0001209191-18-035944 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,871,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2018 Filed Jun 5, 2018 23:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,320 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-035944 · doc4.xml · derivative · entry 13 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,181 Underlying: Common Stock · 10,320 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully vested. Read SEC document |
| June 04, 2018 Filed Jun 5, 2018 23:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 318 | $55.21 | $17,556.78 |
DisclosureSEC source: 0001209191-18-035944 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 110,400 F2 · shares: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $55.00 to $55.45. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 04, 2018 Filed Jun 5, 2018 23:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 600 | $54.58 | $32,748.00 |
DisclosureSEC source: 0001209191-18-035944 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 110,718 F2 · shares: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $54.05 to $54.90. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 04, 2018 Filed Jun 5, 2018 23:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 10,170 | $54.99 | $559,248.30 |
DisclosureSEC source: 0001209191-18-035944 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,860,986 F2 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $54.80 to $55.45. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 04, 2018 Filed Jun 5, 2018 23:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 8,730 | $54.37 | $474,650.10 |
DisclosureSEC source: 0001209191-18-035944 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,871,156 F2 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $53.80 to $54.775. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 04, 2018 Filed Jun 5, 2018 23:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,320 | $3.60 | $37,152.00 |
DisclosureSEC source: 0001209191-18-035944 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,879,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 23:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Tax withholdingCommon Stock | 2,287 | $54.05 | $123,612.35 |
DisclosureSEC source: 0001209191-18-035944 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,869,566 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units. Read SEC document |
| May 17, 2018 Filed May 18, 2018 20:06 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,320 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-031378 · doc4.xml · derivative · entry 12 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,501 Underlying: Common Stock · 10,320 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| May 17, 2018 Filed May 18, 2018 20:06 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 918 | $51.62 | $47,387.16 |
DisclosureSEC source: 0001209191-18-031378 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 111,318 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F7 · price: The shares were sold at prices ranging from $51.30 to $52.05. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 17, 2018 Filed May 18, 2018 20:06 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,100 | $52.26 | $57,486.00 |
DisclosureSEC source: 0001209191-18-031378 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,871,853 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $52.15 to $52.35. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 17, 2018 Filed May 18, 2018 20:06 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 17,800 | $51.62 | $918,836.00 |
DisclosureSEC source: 0001209191-18-031378 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,872,953 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $51.15 to $52.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 17, 2018 Filed May 18, 2018 20:06 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,320 | $3.60 | $37,152.00 |
DisclosureSEC source: 0001209191-18-031378 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,890,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2018 Filed May 18, 2018 20:06 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,320 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-031378 · doc4.xml · derivative · entry 11 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,821 Underlying: Common Stock · 10,320 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| May 16, 2018 Filed May 18, 2018 20:06 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 918 | $52.04 | $47,772.72 |
DisclosureSEC source: 0001209191-18-031378 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 112,236 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $51.70 to $52.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 16, 2018 Filed May 18, 2018 20:06 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 9,010 | $52.29 | $471,132.90 |
DisclosureSEC source: 0001209191-18-031378 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,880,433 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $52.00 to $52.60. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 16, 2018 Filed May 18, 2018 20:06 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 9,890 | $51.71 | $511,411.90 |
DisclosureSEC source: 0001209191-18-031378 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,889,443 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $51.00 to $51.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 16, 2018 Filed May 18, 2018 20:06 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,320 | $3.60 | $37,152.00 |
DisclosureSEC source: 0001209191-18-031378 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,899,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2018 Filed May 4, 2018 21:10 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,320 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-028151 · doc4.xml · derivative · entry 11 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 392,141 Underlying: Common Stock · 10,320 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document |
| May 03, 2018 Filed May 4, 2018 21:10 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 918 | $46.63 | $42,806.34 |
DisclosureSEC source: 0001209191-18-028151 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 113,154 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $46.10 to $46.90. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 03, 2018 Filed May 4, 2018 21:10 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,900 | $47.30 | $137,170.00 |
DisclosureSEC source: 0001209191-18-028151 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,889,013 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $47.10 to $47.70. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 03, 2018 Filed May 4, 2018 21:10 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 16,000 | $46.65 | $746,400.00 |
DisclosureSEC source: 0001209191-18-028151 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,891,913 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $46.10 to $47.075. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 03, 2018 Filed May 4, 2018 21:10 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,320 | $3.60 | $37,152.00 |
DisclosureSEC source: 0001209191-18-028151 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,907,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.